Elisabeth Proenza
Family · Vidalia, GANPI 1619591120
Payments from drug & device makers
Across 183 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$692
- AstraZeneca$321
- Lilly USA, LLC$313
- Pfizer$307
- AbbVie$173
- Amgen$119
- plus $990 from 25 others
What the payments were for
- Food & beverage$2,915100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,915 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 176 | $209,136 |
| MounjaroTirzepatide | 105 | $116,220 |
| EliquisApixaban | 92 | $74,145 |
| JardianceEmpagliflozin | 49 | $52,234 |
| FarxigaDapagliflozin Propanediol | 29 | $44,483 |
| JanuviaSitagliptin Phosphate | 38 | $43,290 |
| RybelsusSemaglutide | 27 | $31,863 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $29,370 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $26,661 |
| LinzessLinaclotide | 27 | $24,221 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $23,978 |
| XareltoRivaroxaban | 25 | $23,649 |
| TrulicityDulaglutide | 17 | $22,018 |
| GemtesaVibegron | 20 | $19,344 |
| Repatha SureclickEvolocumab | 27 | $14,840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $692 | $240,999203 claims |
| Lilly USA, LLCMounjaro, Trulicity | $313 | $138,238122 claims |
| PfizerEliquis | $307 | $74,14592 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $321 | $60,70271 claims |
| Boehringer IngelheimJardiance | $103 | $52,23449 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $68 | $40,05656 claims |
| AbbVieLinzess, Synthroid | $173 | $32,139135 claims |
| Johnson & JohnsonXarelto | $13 | $23,64925 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $19 | $19,34420 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $54 | $4,856432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.
Other family in Vidalia
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.